PILot Aortic Triflo Valve Study

NCT ID: NCT06119607

Last Updated: 2025-08-15

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-30
• Study Completion Date: 2029-06-30

Brief Summary

A prospective, single arm, exploratory clinical investigation to assess preliminary safety and collect performance and effectiveness data of the TRIFLO Heart Valve.

Detailed Description

Up to 10 Subjects requiring aortic valve replacement of the native valve will be included in this First in Human clinical investigation on the TRIFLO Heart Valve device in Europe. The study is prospective, single-arm-open-label-non-randomized.

Conditions

Aortic Valve Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TRIFLO

Group Type: EXPERIMENTAL

TRIFLO Heart Valve

Intervention Type: DEVICE

Surgical Aortic Valve Replacement - Mechanical Valve

Interventions

TRIFLO Heart Valve

Surgical Aortic Valve Replacement - Mechanical Valve

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient is between 18 and 75 years old.
• Patient with symptomatic aortic valve disease (stenosis and/or regurgitation) where aortic valve replacement with a mechanical valve is recommended according to the decision of the site heart team and validated by the independent clinical review committee.
• Patient with a low surgical mortality risk with EuroSCORE II < 4%.
• Patient with echocardiographic Left Ventricular Ejection Fraction (LVEF) > 35% using Transthoracic Echocardiogram (TTE).
• Assessment using echocardiography imaging modality of annular suitable for a valve of 21 mm in size and acceptable for the Body Surface Area (BSA) of the patient to avoid any patient prosthesis mismatch.
• Participants are able to take low-dose aspirin at a dose of 75 -100 mg daily or have a documented contraindication to aspirin use.
• Patient is geographically stable and willing to return to implanting site for follow-up visits up to 5 years.
• Patient has been adequately informed of risks and requirements of the clinical investigation and is willing and able to provide informed consent for participation.
• In opinion of the Investigator, the patient has a life expectancy of at least 5 years.

Exclusion Criteria

• Patient has a pre-existing prosthetic valve (including TAVI) or annuloplasty device or requires replacement or repair of the mitral, pulmonary or tricuspid valve.
• Patient is maintained on any permanent or long-term anticoagulant therapy (i.e. any A-fib, deep vein thrombosis, lung embolism, percutaneous coronary intervention (PCI), previous ST-elevation myocardial infarct (STEMI)).
• Patient has a history of vascular-related neurological events (TIA, stroke, intracranial bleeding) occurring within 6 months prior to enrollment.
• Patient has active endocarditis/myocarditis or other systemic infection within 3 months of the scheduled surgery.
• Patient has an additional cardiovascular pathology which would increase surgical risk of morbidity or mortality.
• Patient is planning another unrelated surgical procedure outside of the cardiac area within the next 12 months of study device implantation.
• Patient has renal insufficiency as determined by creatinine (S-Cr) level as ≥ 1.5 mg/dL or end stage renal disease requiring chronic dialysis at screening visit.
• Patient presents hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery.
• Patient has active, clinically relevant bleeding disorder (documented leukopenia (WBC < 4.0 x 103/μL), acute anemia (Hgb < 10.0 g/dL or 6 mmol/L), thrombocytopenia (platelet count < 100 x 103/μL) or history of bleeding diathesis or coagulopathy).
• Patient has had prior organ transplant or is currently an organ transplant candidate.
• Patient is currently participating or participated in the last 30 days in another investigational device or drug trial.
• Patient who is pregnant, plan to become pregnant during the time of the clinical trial or is lactating or patient of childbearing age not taking any effective method of birth control.
• Patient is considered part of vulnerable population (i.e. prison inmates).
• Patient with documented history of substance (drug or alcohol) abuse within the last 5 years prior to implantation procedure.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Veranex

UNKNOWN

Sponsor Role: collaborator

Novostia SA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kęstutis Ručinskas, Prof.

Role: PRINCIPAL_INVESTIGATOR

Vilnius University Hospital Santaros Clinics

Locations

Vilnius University Hospital Santaros Klinikos

Vilnius, Vilnius County, Lithuania

Countries

Lithuania

Other Identifiers

CIV-LT-23-08-043783

Identifier Type: OTHER

Identifier Source: secondary_id

100144

Identifier Type: -

Identifier Source: org_study_id